Fasting blood glucose for insulin adjustment with insulin glargine or NPH insulin combined with sulphonylurea in Type 2 diabetes

被引：0
|
作者：
Haupt, A
Eckert, H
Schweitzer, MA
Peiker, J
Häring, HU
Fritsche, A
机构：
[1] Aventis Pharma Deutschland GmbH, Bad Soden am Taunus, Germany
[2] Univ Tubingen, Med Klin, D-7400 Tubingen, Germany
来源：
DIABETOLOGIA | 2004年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
743
引用
收藏
页码：A269 / A269
页数：1
相关论文
共 50 条
  • [21] Duration of diabetes and hypoglycaemia rates in type 2 diabetes patients treated with insulin glargine vs NPH insulin
    Dailey, G.
    Aurand, L.
    Garg, S.
    [J]. DIABETOLOGIA, 2011, 54 : S262 - S262
  • [22] Insulin glargine is associated with less hypoglycaemia than NPH insulin in older patients with Type 2 diabetes
    Riddle, M
    Massi-Benedetti, M
    Häring, HU
    Dailey, G
    Murray, F
    Lin, Z
    Rosenstock, J
    [J]. DIABETOLOGIA, 2004, 47 : A328 - A328
  • [23] Safety and efficacy of insulin glargine compared with NPH insulin in older adults with type 2 diabetes mellitus
    Lee, P. G.
    Chang, A. M.
    Blaum, C.
    Vlajnic, A.
    Miller, M. F.
    Halter, J. B.
    [J]. DIABETOLOGIA, 2009, 52 : S382 - S382
  • [24] Effects of insulin degludec and insulin glargine on day-to-day fasting blood glucose variability in patients with type 1 diabetes
    Nakamura, T.
    Sakaguchi, K.
    So, A.
    Nakajima, S.
    Takabe, M.
    Komada, H.
    Okuno, Y.
    Hirota, Y.
    Nakamura, T.
    Iida, K.
    Kajikawa, M.
    Nagata, M.
    Ogawa, W.
    Seino, S.
    [J]. DIABETOLOGIA, 2014, 57 : S390 - S390
  • [25] Risk of microvascular events following initiation of insulin glargine or NPH insulin in type 2 diabetes in the US
    Kennedy, L.
    Vinik, A.
    Chaudhuri, A.
    Rhoads, G.
    Vaur, L.
    Fonseca, V. A.
    [J]. DIABETOLOGIA, 2009, 52 : S453 - S453
  • [26] Economic evaluation of the use of insulin glargine compared with NPH insulin in patients with Type 2 diabetes in Spain
    Rodríguez, J
    Terrés, CR
    Bolinder, B
    de Pablos, P
    [J]. DIABETOLOGIA, 2004, 47 : A344 - A344
  • [27] Economic impact of nocturnal hypoglycemia associated with the treatment of type 2 diabetes with insulin glargine or NPH insulin
    Rubio-Terres, Carlos
    Alvarez Guisasola, Fernando
    Navarro Perez, Jorge
    Delgado Alvarez, Elias
    Azriel Mira, Sharona
    Magana, Ana
    [J]. AVANCES EN DIABETOLOGIA, 2013, 29 (01): : 19 - 26
  • [28] Concomitant use of insulin glargine and NPH in type I diabetes
    Khadilkar, VV
    Khadilkar, AV
    [J]. INDIAN PEDIATRICS, 2005, 42 (08) : 796 - 800
  • [29] Therapy in type 2 diabetes: Insulin glargine vs. 2 NPH insulin both in combination with glimepiride
    Eliaschewitz, FG
    Calvo, C
    Valbuena, H
    Ruiz, M
    Aschner, P
    Villena, J
    Ramirez, LA
    Jimenez, J
    [J]. ARCHIVES OF MEDICAL RESEARCH, 2006, 37 (04) : 495 - 501
  • [30] 2-year glycaemic control after initiation of insulin glargine or NPH insulin in type 2 diabetes
    Leahy, J. L.
    Dain, M. -P.
    Rhoads, G. G.
    Kennedy, L.
    [J]. DIABETOLOGIA, 2008, 51 : S405 - S405
12345